4Turner RC, Millns,Neil H,et al. For the united kingttom prospective diabetes study group. Risk factors for coronary artery disease in non-in-sulin dependent diabetes mellitus: united kinglom prospective diabetes study (UKPDS: 23) [J]. BMJ, 1998,316: 823.
5Vittorio PA, Jonathan N, Donna K, et al, Effect of type 2 diabetes mellitus on left ventricular geometary and systolic funcyion in hypertensive subjects: Hypertension Genetic Epidemiology Network(Hyper GEN) Study[J]. Circulation, 2001,103 ( 1 ) : 102 - 107.
6Gami AS, Montofi VM, Erwin PJ, et al. Systematic review of lipid lowering for primary prevention of coronary heart diease in diabetes[J]. BMJ,2003, 326(7388) :528 - 529.
二级参考文献7
1Luc G. Mechanisms of action of hypolipidemic agents,Therapie 2000 ; 55 (6) : 661 - 668.
2Chinetti G, Fruchart JC, Staeles B, Peroxisome prolifera-toractivated receptors(PPARs): nuclear receptors with functions in the vascular wall, Z Kardiol 2001;90 Suppl 3:125-132.
3Steinmez A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes 2001 ; 109(4) :548- 559.
4Rubbins H B, Roins S J, Collins D, et al. Gemfibrozil for the second prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group,NEngl J Med 1999;341:410-418.
5Goa K L, Barradell L B, Plosker G L, Bezafibrate, and update of its pharmacology and use in the management of dyslipidaemia. Drugs 1996;52(5) :725-753.
6Frick M H, Syvanne M, Nieminen M S, et al. Prevention of angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol, Circulation 1997;96:2137-2143.
7Diabetes atherosclerosis Intervention Study Investigators.Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Dlabetes atherosclerosis Intervention Study,a radomized studies. Lancet 2001 ; 357 : 905- 910.
2WolffAA,Rotmensch HH,StanleyWC. Metabolic approaches to the treatment of ischemic heart disease:the clinicians′ perspective[J].Heart Failure Reviews,2002,(02):187-203.
